1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow pasireotide: new trials by email Literature Review of pasireotide trials Research Report on pasireotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor SOM 230 / Pasireotide - Ductal Carcinoma in Situ | Phase 1 / Phase 2 | Terminated | NYU Langone Health | 9 | 2011-06-01 | 2017-12-27 |
Carcinoma, Intraductal, Noninfiltrating (1)
United States (1)